Journal article
Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity
Transfusion (Philadelphia, Pa.), Vol.56(11), pp.2848-2856
11/2016
DOI: 10.1111/trf.13795
PMID: 27600855
Abstract
Hydroxyethyl starch (HES) is reportedly associated with an increased risk of renal failure and death when used for fluid resuscitation in critically ill patients. HES can be used during therapeutic leukocytapheresis (TL) procedures to enhance cell separation. The purpose of this study was to evaluate the occurrence of adverse events associated with HES during TL procedures.
We performed a retrospective review of patients who underwent TL with and without HES in the period 2009 to 2013 at six academic medical institutions.
A difference-in-difference regression analysis was used to estimate the mean change before and after TL in selected outcomes in the HES group relative to the average change in the non-HES group. Selected outcomes included serum creatinine, estimated glomerular filtration rate (eGFR), and white blood cell (WBC) count. A total of 195 patients who underwent 278 TL procedures were studied. We found no significant differences in serum creatinine levels and eGFR on Days 1 and 7 after TL procedure between patients who received and those who did not receive HES. The rate of adverse events and overall and early mortality were similar in both groups. Patients with acute myeloid leukemia who received HES had greater WBC reduction when HES was used. Additionally, patients who received HES had improvement in pulmonary leukostasis symptoms.
HES, used at low doses during TL procedures, was not associated with adverse events previously ascribed to its use as a volume expander.
Details
- Title: Subtitle
- Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity
- Creators
- Monica B Pagano - Department of Laboratory Medicine, University of Washington, Seattle, WashingtonCharles Harmon - Department of Pathology, University of Michigan, Ann Arbor, MichiganLaura Cooling - Department of Pathology, University of Michigan, Ann Arbor, MichiganLaura Connelly-Smith - Division of Hematology, University of Washington, Seattle, WashingtonSteven A Mann - University of Alabama School of Medicine, Birmingham, AlabamaHuy P Pham - Department of Pathology, University of Alabama at Birmingham, Birmingham, AlabamaMarisa B Marques - Department of Pathology, University of Alabama at Birmingham, Birmingham, AlabamaAnnette J Schlueter - Department of Pathology, University of Iowa, Iowa City, IowaRosemary Case - Division of Transfusion Medicine, Johns Hopkins Medical Institutions, Baltimore, MarylandKaren E King - Division of Transfusion Medicine, Johns Hopkins Medical Institutions, Baltimore, MarylandGuido Cataife - Health Division, IMPAQ International, Columbia, MarylandYanyun Wu - Bloodworks Northwest, Seattle, WashingtonEdward C C Wong - Division of Laboratory Medicine, Departments of Pediatrics and Pathology, Children's National Medical Center, George Washington School of Medicine and Health Sciences, Washington, DCJeffrey L Winters - Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota
- Resource Type
- Journal article
- Publication Details
- Transfusion (Philadelphia, Pa.), Vol.56(11), pp.2848-2856
- DOI
- 10.1111/trf.13795
- PMID
- 27600855
- NLM abbreviation
- Transfusion
- ISSN
- 0041-1132
- eISSN
- 1537-2995
- Publisher
- United States
- Grant note
- UL1 TR000075 / NCATS NIH HHS
- Language
- English
- Date published
- 11/2016
- Academic Unit
- Pathology
- Record Identifier
- 9984047798702771
Metrics
16 Record Views